Clinical TrialsSetmelanotide hits in the Phase 3 TRANSCEND trial for hypothalamic obesity, unlocking a multi billion-dollar opportunity and derisking the next-generation MC4R agonists.
Market PotentialThe stock is valued with expectations of a $1B+ opportunity in the HO market, with potential to exceed this figure.
Product DevelopmentThe anticipated Phase 2 data for bivamelagon in hypothalamic obesity supports a favorable risk/reward balance, with potential for significant market expansion.